Pre-vaccination immune response to COVID-19 in a population in Northeast Portugal
© 2021. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland..
PURPOSE: To study the immunization status and IgM and IgG antibody behavior against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an unvaccinated population of Northeast Portugal (including RT-PCR diagnosed and undiagnosed individuals).
METHODS: Application of a clinical-epidemiological survey, and analysis of IgM and IgG SARS-COV-2 antibodies (against N core protein) in 362 participants that voluntarily sought the laboratory for testing.
RESULTS: At the time of the analysis, 31.7% (n = 114) of the study population had a previous SARS-CoV-2 diagnosis, 48.3% of which were asymptomatic, and 71.9% IgG seropositive. Of these, 83.3% and 60% were, respectively, IgM and IgG seropositive within 2 weeks after the initial diagnosis. Both antibodies peaked in the 3rd week post diagnosis, with titers decreasing over the following weeks, until a state of seronegativity was achieved after the 6th week for IgM, and the 21st for IgG. Symptomatic patients showed higher IgM and IgG values, when compared to asymptomatic ones. Fever, the most reported symptom, was found to be positively associated with IgM values. Ages of ≤ 18-year-old and ≥ 65-year-old exhibited the highest median values for both IgM and IgG, with the former being statistically significant. In the undiagnosed group, 13.9% and 11.1% were seropositive for IgM and IgG, respectively.
CONCLUSION: IgM and IgG displayed a similar initial increase (within 1/2 weeks), with IgG having a significant decrease after the 21st week post-diagnosis, translating a loss of immunity at this point. The youngest and oldest symptomatic age groups were found to be the highest responders. Antibody assays enabled the identification of previously undiagnosed participants.
| Errataetall: |
CommentIn: Ir J Med Sci. 2022 Oct;191(5):2219. - PMID 34713417 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:191 |
|---|---|
| Enthalten in: |
Irish journal of medical science - 191(2022), 5 vom: 12. Okt., Seite 1951-1958 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Duro, Mary [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 23.09.2022 Date Revised 01.11.2022 published: Print-Electronic CommentIn: Ir J Med Sci. 2022 Oct;191(5):2219. - PMID 34713417 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11845-021-02799-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331836955 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331836955 | ||
| 003 | DE-627 | ||
| 005 | 20231225214341.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11845-021-02799-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1106.xml |
| 035 | |a (DE-627)NLM331836955 | ||
| 035 | |a (NLM)34642902 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Duro, Mary |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pre-vaccination immune response to COVID-19 in a population in Northeast Portugal |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.09.2022 | ||
| 500 | |a Date Revised 01.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Ir J Med Sci. 2022 Oct;191(5):2219. - PMID 34713417 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland. | ||
| 520 | |a PURPOSE: To study the immunization status and IgM and IgG antibody behavior against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an unvaccinated population of Northeast Portugal (including RT-PCR diagnosed and undiagnosed individuals) | ||
| 520 | |a METHODS: Application of a clinical-epidemiological survey, and analysis of IgM and IgG SARS-COV-2 antibodies (against N core protein) in 362 participants that voluntarily sought the laboratory for testing | ||
| 520 | |a RESULTS: At the time of the analysis, 31.7% (n = 114) of the study population had a previous SARS-CoV-2 diagnosis, 48.3% of which were asymptomatic, and 71.9% IgG seropositive. Of these, 83.3% and 60% were, respectively, IgM and IgG seropositive within 2 weeks after the initial diagnosis. Both antibodies peaked in the 3rd week post diagnosis, with titers decreasing over the following weeks, until a state of seronegativity was achieved after the 6th week for IgM, and the 21st for IgG. Symptomatic patients showed higher IgM and IgG values, when compared to asymptomatic ones. Fever, the most reported symptom, was found to be positively associated with IgM values. Ages of ≤ 18-year-old and ≥ 65-year-old exhibited the highest median values for both IgM and IgG, with the former being statistically significant. In the undiagnosed group, 13.9% and 11.1% were seropositive for IgM and IgG, respectively | ||
| 520 | |a CONCLUSION: IgM and IgG displayed a similar initial increase (within 1/2 weeks), with IgG having a significant decrease after the 21st week post-diagnosis, translating a loss of immunity at this point. The youngest and oldest symptomatic age groups were found to be the highest responders. Antibody assays enabled the identification of previously undiagnosed participants | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Immune response | |
| 650 | 4 | |a PCR diagnosis | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Vaccination | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 700 | 1 | |a Duro, Inês |e verfasserin |4 aut | |
| 700 | 1 | |a Rebelo, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Filipa |e verfasserin |4 aut | |
| 700 | 1 | |a Pires, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Jacinto, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Pimentel, Marilda |e verfasserin |4 aut | |
| 700 | 1 | |a Almeida, Cristina Maria Nunes |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Irish journal of medical science |d 1945 |g 191(2022), 5 vom: 12. Okt., Seite 1951-1958 |w (DE-627)NLM000148970 |x 1863-4362 |7 nnns |
| 773 | 1 | 8 | |g volume:191 |g year:2022 |g number:5 |g day:12 |g month:10 |g pages:1951-1958 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11845-021-02799-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 191 |j 2022 |e 5 |b 12 |c 10 |h 1951-1958 | ||